Iconovo AB (publ) (ICO.ST)
SEK 4.17
(-2.11%)
SEK 4.17
(-2.11%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 17.57 Million SEK | -412.05% |
| 2022 | 17.24 Million SEK | -19.07% |
| 2021 | 21.3 Million SEK | 2.39% |
| 2020 | 20.8 Million SEK | 29.3% |
| 2019 | 16.09 Million SEK | 35.58% |
| 2018 | 11.87 Million SEK | -42.62% |
| 2017 | 20.68 Million SEK | 26.13% |
| 2016 | 16.4 Million SEK | 1648.49% |
| 2015 | -1.05 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 3.29 Million SEK | -34.95% |
| 2024 Q1 | -10.39 Million SEK | 7.44% |
| 2024 Q2 | 5.05 Million SEK | 148.66% |
| 2023 FY | -53.81 Million SEK | -412.05% |
| 2023 Q4 | -11.23 Million SEK | -350.75% |
| 2023 Q3 | 4.47 Million SEK | -13.21% |
| 2023 Q2 | 5.16 Million SEK | 57.3% |
| 2023 Q1 | 3.28 Million SEK | -4.39% |
| 2022 Q2 | 4.98 Million SEK | -11.75% |
| 2022 FY | 17.24 Million SEK | -19.07% |
| 2022 Q4 | 3.43 Million SEK | 8.15% |
| 2022 Q3 | 3.17 Million SEK | -36.39% |
| 2022 Q1 | 5.65 Million SEK | 13.64% |
| 2021 FY | 21.3 Million SEK | 2.39% |
| 2021 Q3 | 6.28 Million SEK | 13.71% |
| 2021 Q2 | 5.53 Million SEK | 22.48% |
| 2021 Q4 | 4.97 Million SEK | -20.9% |
| 2021 Q1 | 4.51 Million SEK | -42.54% |
| 2020 Q4 | 7.85 Million SEK | 23.49% |
| 2020 Q3 | 6.36 Million SEK | 84.6% |
| 2020 Q2 | 3.44 Million SEK | 9.78% |
| 2020 FY | 20.8 Million SEK | 29.3% |
| 2020 Q1 | 3.14 Million SEK | 259.06% |
| 2019 Q4 | 874.5 Thousand SEK | -80.09% |
| 2019 Q3 | 4.39 Million SEK | 6.24% |
| 2019 Q2 | 4.13 Million SEK | -38.22% |
| 2019 Q1 | 6.69 Million SEK | 24.07% |
| 2019 FY | 16.09 Million SEK | 35.58% |
| 2018 Q4 | 5.39 Million SEK | 207.39% |
| 2018 Q2 | 4.89 Million SEK | 2897.14% |
| 2018 Q1 | -175 Thousand SEK | -101.43% |
| 2018 FY | 11.87 Million SEK | -42.62% |
| 2018 Q3 | 1.75 Million SEK | -64.15% |
| 2017 Q4 | 12.22 Million SEK | 9572.87% |
| 2017 Q3 | -129 Thousand SEK | -101.63% |
| 2017 Q2 | 7.89 Million SEK | 422.22% |
| 2017 FY | 20.68 Million SEK | 26.13% |
| 2017 Q1 | 1.51 Million SEK | 0.0% |
| 2016 FY | 16.4 Million SEK | 1648.49% |
| 2015 FY | -1.05 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | -231.842% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 94.152% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 94.152% |
| Arcoma AB | 11.07 Million SEK | -58.772% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 87.443% |
| BICO Group AB (publ) | 1.83 Billion SEK | 99.04% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 92.961% |
| CellaVision AB (publ) | 463.04 Million SEK | 96.204% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | -486.508% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 161.862% |
| C-Rad AB (publ) | 66.01 Million SEK | 73.373% |
| Duearity AB (publ) | -4.17 Million SEK | 520.719% |
| Dignitana AB (publ) | 58.97 Million SEK | 70.193% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 142.052% |
| Getinge AB (publ) | 13.43 Billion SEK | 99.869% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 135.003% |
| Integrum AB (publ) | 690.56 Thousand SEK | -2445.413% |
| Luxbright AB (publ) | -2.79 Million SEK | 728.475% |
| Mentice AB (publ) | 236.38 Million SEK | 92.564% |
| OssDsign AB (publ) | 83.64 Million SEK | 78.985% |
| Paxman AB (publ) | 12.61 Million SEK | -39.306% |
| Promimic AB (publ) | 38.51 Million SEK | 54.362% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 134.634% |
| SciBase Holding AB (publ) | 16.03 Million SEK | -9.607% |
| ScandiDos AB (publ) | 47.55 Million SEK | 63.037% |
| Sectra AB (publ) | 557.55 Million SEK | 96.847% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 83.871% |
| Senzime AB (publ) | 8.33 Million SEK | -110.789% |
| SpectraCure AB (publ) | -9.22 Million SEK | 290.585% |
| Stille AB | 132.17 Million SEK | 86.701% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 99.111% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 95.784% |